Rac1 promotes the formation of heterotypic cell-in-cell structure.

Tao HU; Pengfei Feng; Haoyuan LI; Lulin Zhou; Zubiao Niu; Yinuo Huang; Xiaoning Wang; Chenxi Wang; Hui Liu; Chengjun WU

Return

Rac1 promotes the formation of heterotypic cell-in-cell structure.

Author: Tao HU ¹ ; Pengfei FENG ² ; Haoyuan LI ¹ ; Lulin ZHOU ² ; Zubiao NIU ² ; Yinuo HUANG ² ; Xiaoning WANG ³ ; Chenxi WANG ² ; Hui LIU ¹ ; Chengjun WU ¹
Author Information

1. School of Biomedical Engineering, Dalian University of Technology, Dalian 116024, Liaoning, China.
2. Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100071, China.
3. Chinese People's Liberation Army Medical School, Beijing 100853, China.
Publication Type:Journal Article
Keywords: Ras-related C3 botulinum toxin substrate 1; heterotypic cell-in-cell structure; immunotherapy; tumorigenesis
From: Chinese Journal of Biotechnology 2023;39(10):4123-4134
CountryChina
Language:Chinese
Abstract: Heterotypic cell-in-cell structures (heCICs) are closely related to tumor development and progression, and have become a new frontier in life science research. Ras-related C3 botulinum toxin substrate 1 (Rac1) belongs to the classic Rho GTPase, which plays a key role in regulating the cytoskeleton and cell movement. To investigate the role and mechanism of Rac1 in the formation of heCICs, tumor cells and immune killer cells were labeled with cell-tracker, respectively, to establish the heCICs model. Upon treatment with the Rac1 inhibitor NSC23766, the formation of heCICs between tumor and immune cells was significantly reduced. The plasmid pQCXIP-Rac1-EGFP constructed by gene cloning was packaged into pseudoviruses that subsequently infect tumor cells to make cell lines stably expressing Rac1. As a result, the formation of heCICs was significantly increased upon Rac1 overexpression. These results demonstrated a promotive role of Rac1 in heCICs formation, which may facilitate treating cell-in-cell related diseases, such as tumors, by targeting Rac1.